36-month evaluation of intravitreous aflibercept injection for wet age-related macular degeneration in patients previously treated with ranibizumab or bevacizumab

Felipe F. Conti, Fabiana Q. Silva, Sunil K. Srivastava, Justis P. Ehlers, Andrew Schachat, Rishi P. Singh

Research output: Contribution to journalArticle

Abstract

Background and Objective: In the ASSESS study, patients with neovascular age-related macular degeneration transitioned from other anti-vascular endothelial growth factor therapies to intravitreous aflibercept (Eylea; Regeneron, Tarrytown, NY) injections (IAI). The purpose was to determine the 36-month outcomes following the change from a fixed 24-month IAI dosing regimen to a routine clinical practice regimen. Patients and Methods: Patients were treated with a fixed bimonthly regimen for the first 2 years. In the third year, patients were managed according to routine clinical practice. Results: A total of 18 patients completed the 36 months and were considered for statistical analyses. At 36 months, a nonsignificant decrease of -37.8 μm in central subfield thickness and a nonsignificant gain of 5.8 letters from baseline were observed. Conclusion: Despite the significant visual and anatomical gains observed in the 2 years of fixed-dosing IAI, there was gradual decline in these improvements when patients were transitioned to a variable regimen.

LanguageEnglish (US)
Pages179-185
Number of pages7
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume49
Issue number3
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Fingerprint

Macular Degeneration
Injections
Vascular Endothelial Growth Factor A
Bevacizumab
aflibercept
Ranibizumab

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Cite this

36-month evaluation of intravitreous aflibercept injection for wet age-related macular degeneration in patients previously treated with ranibizumab or bevacizumab. / Conti, Felipe F.; Silva, Fabiana Q.; Srivastava, Sunil K.; Ehlers, Justis P.; Schachat, Andrew; Singh, Rishi P.

In: Ophthalmic Surgery Lasers and Imaging Retina, Vol. 49, No. 3, 01.03.2018, p. 179-185.

Research output: Contribution to journalArticle

@article{56eddd38f3634ae7b480ed4084e26ef5,
title = "36-month evaluation of intravitreous aflibercept injection for wet age-related macular degeneration in patients previously treated with ranibizumab or bevacizumab",
abstract = "Background and Objective: In the ASSESS study, patients with neovascular age-related macular degeneration transitioned from other anti-vascular endothelial growth factor therapies to intravitreous aflibercept (Eylea; Regeneron, Tarrytown, NY) injections (IAI). The purpose was to determine the 36-month outcomes following the change from a fixed 24-month IAI dosing regimen to a routine clinical practice regimen. Patients and Methods: Patients were treated with a fixed bimonthly regimen for the first 2 years. In the third year, patients were managed according to routine clinical practice. Results: A total of 18 patients completed the 36 months and were considered for statistical analyses. At 36 months, a nonsignificant decrease of -37.8 μm in central subfield thickness and a nonsignificant gain of 5.8 letters from baseline were observed. Conclusion: Despite the significant visual and anatomical gains observed in the 2 years of fixed-dosing IAI, there was gradual decline in these improvements when patients were transitioned to a variable regimen.",
author = "Conti, {Felipe F.} and Silva, {Fabiana Q.} and Srivastava, {Sunil K.} and Ehlers, {Justis P.} and Andrew Schachat and Singh, {Rishi P.}",
year = "2018",
month = "3",
day = "1",
doi = "10.3928/23258160-20180221-05",
language = "English (US)",
volume = "49",
pages = "179--185",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "3",

}

TY - JOUR

T1 - 36-month evaluation of intravitreous aflibercept injection for wet age-related macular degeneration in patients previously treated with ranibizumab or bevacizumab

AU - Conti, Felipe F.

AU - Silva, Fabiana Q.

AU - Srivastava, Sunil K.

AU - Ehlers, Justis P.

AU - Schachat, Andrew

AU - Singh, Rishi P.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background and Objective: In the ASSESS study, patients with neovascular age-related macular degeneration transitioned from other anti-vascular endothelial growth factor therapies to intravitreous aflibercept (Eylea; Regeneron, Tarrytown, NY) injections (IAI). The purpose was to determine the 36-month outcomes following the change from a fixed 24-month IAI dosing regimen to a routine clinical practice regimen. Patients and Methods: Patients were treated with a fixed bimonthly regimen for the first 2 years. In the third year, patients were managed according to routine clinical practice. Results: A total of 18 patients completed the 36 months and were considered for statistical analyses. At 36 months, a nonsignificant decrease of -37.8 μm in central subfield thickness and a nonsignificant gain of 5.8 letters from baseline were observed. Conclusion: Despite the significant visual and anatomical gains observed in the 2 years of fixed-dosing IAI, there was gradual decline in these improvements when patients were transitioned to a variable regimen.

AB - Background and Objective: In the ASSESS study, patients with neovascular age-related macular degeneration transitioned from other anti-vascular endothelial growth factor therapies to intravitreous aflibercept (Eylea; Regeneron, Tarrytown, NY) injections (IAI). The purpose was to determine the 36-month outcomes following the change from a fixed 24-month IAI dosing regimen to a routine clinical practice regimen. Patients and Methods: Patients were treated with a fixed bimonthly regimen for the first 2 years. In the third year, patients were managed according to routine clinical practice. Results: A total of 18 patients completed the 36 months and were considered for statistical analyses. At 36 months, a nonsignificant decrease of -37.8 μm in central subfield thickness and a nonsignificant gain of 5.8 letters from baseline were observed. Conclusion: Despite the significant visual and anatomical gains observed in the 2 years of fixed-dosing IAI, there was gradual decline in these improvements when patients were transitioned to a variable regimen.

UR - http://www.scopus.com/inward/record.url?scp=85044183327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044183327&partnerID=8YFLogxK

U2 - 10.3928/23258160-20180221-05

DO - 10.3928/23258160-20180221-05

M3 - Article

VL - 49

SP - 179

EP - 185

JO - Ophthalmic Surgery Lasers and Imaging Retina

T2 - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

SN - 2325-8160

IS - 3

ER -